Clorox — Fiscal 2018 Form 10-K Summary
Reporting period: The filing covers the fiscal year ended June 30, 2018, not a standalone 2017 fourth quarter as the request metadata suggests. The filing’s MD&A and audited financial statements are incorporated by reference but are not included in the supplied text, limiting the financial detail available here.
Business context and results
Clorox is a consumer and professional products company operating in Cleaning, Household, Lifestyle and International. It reported fiscal 2018 net sales of $6.124 billion, with more than 80% of sales from brands holding No. 1 or No. 2 positions in their categories.
| Metric | FY2018 | FY2017 | Change |
|---|---|---|---|
| Net sales | $6.124 billion | $5.973 billion | Up 3% as reported |
| Continuing-operations earnings before income taxes | $1.054 billion | $1.033 billion | Up $21 million |
| Diluted EPS from continuing operations | Not stated in supplied text | Not stated in supplied text | Up 17% |
Segment sales were Cleaning $2.060 billion, Household $1.959 billion, Lifestyle $1.077 billion and International $1.028 billion. Versus FY2017, Lifestyle sales increased from $1.000 billion, Cleaning from $2.002 billion and International from $1.010 billion; Household was nearly unchanged at $1.961 billion. Nutranext, acquired in April 2018, is included in Lifestyle.
Margins, net income, operating cash flow, free cash flow and liquidity: The supplied filing text does not provide clear values for these measures. It reports more than $2 billion of debt at June 30, 2018; a clear breakdown of debt maturities and liquidity balances is not provided here.
Material changes and capital allocation
- Clorox acquired 100% of Nutranext for $681 million in April 2018, expanding its health and wellness business.
- The company paid $450 million in dividends in FY2018 and announced a 14% quarterly dividend increase in February 2018.
- In May 2018, the board authorized a new $2 billion open-market share repurchase program. Clorox repurchased 749,000 shares for $95 million during FY2018 under the open-market program.
- The Glad venture agreement with Procter & Gamble was extended to January 2026. Clorox’s estimated fair value of its obligation to purchase P&G’s 20% interest was $631 million at June 30, 2018, compared with $458 million a year earlier; $341 million was recognized as a liability.
- The Tax Cuts and Jobs Act affected FY2018 tax accounting. Certain effects, including deferred-tax revaluation and transition tax, were provisional; management expected the Act to reduce future effective tax rates and benefit cash flow.
Outlook, commentary and risks
Clorox’s long-term goals are annual net sales growth of 3–5%, EBIT margin growth of 25–50 basis points and free cash flow equal to 11–13% of net sales. For FY2019, management anticipated continued competition, a more challenging retail environment, rising logistics and commodity costs, currency fluctuations and difficult conditions in some international markets. The company also expected commodity cost increases to continue and had implemented or planned price increases across a significant portion of its portfolio.
Key disclosed risks include private-label and e-commerce competition, potential volume losses from price increases, elevated raw-material and transportation costs, reliance on major retailers, foreign-exchange and inflation exposure, acquisition integration, cybersecurity and regulatory risks, and more than $2 billion of debt. Walmart represented 26% of FY2018 sales, and the five largest customers accounted for nearly half of sales. Argentina was designated highly inflationary effective July 1, 2018, with remeasurement effects expected to be recorded in FY2019.
Environmental remediation liabilities were $28 million at June 30, 2018; the company said its exposure could exceed the amount recorded. Management stated that routine litigation, based on its analysis, was not expected to have a material adverse effect in aggregate, while noting that litigation outcomes cannot be predicted with certainty.
Important facts for investors to verify
- Consult Exhibit 99.1 for full audited statements, including net income, margins, cash flow, cash balances, debt detail and FY2018 tax impacts.
- Review the FY2019 earnings outlook and the expected effects of input-cost inflation, pricing actions and volume trends.
- Assess Nutranext’s contribution, integration progress and acquisition-related costs.
- Track the Glad obligation’s valuation and accounting impact, along with the eventual cash requirement at agreement termination.
- Monitor customer concentration, especially Walmart, and Clorox’s ability to sustain sales and margins amid retailer and private-label competition.